Shares of Endo Health (NASDAQ: ENDP) declined recently on news the FDA rejected Endo's Opana claims, allowing generic to remain ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE